Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon May 17, 2022 9:39am

98 Views

Post# 34688840

RE:RE:Broken News

n the 3rd last Sedar News Release (does Farewell get a discount for using Sedar to exclusively handle his News?)

Bob mentions :" .... had to make the difficult decision to use funds earlier earmarked for the balance of the audit fee to be allocated instead for research and development expenses for the Company’s ongoing Phase 1 clinical study in Australia. If it had not done so it would have faced research and development delays."

He also lists an email address that doesn't work.

Questions:

At what point is he in the Phase 1 study?

Why list a phony email address?

Has anyone tried to phone him? On SEDAR it's "888-861-2008"

Paid insiders need not reply to these questions since they......well we know why by now .

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario